Aquestive Therapeutics Stock Earnings Reports

Aquestive reported progress on regulatory, clinical, commercial and financing fronts in Q1 2026. Key operational updates: completed a Type A face-to-face FDA meeting, MHRA teleconference, submitted a pediatric investigational plan to EMA, and submitted a human factors protocol to FDA; human factors and a PK study for Anaphylm are underway with management expecting top-line human factors (and potentially PK) data in time for the August earnings call and targeting a Q3 2026 NDA resubmission (company expects a Type 2/6-month review but will request expedited handling). Commercial preparations continue (plans for a 75-person U.S. sales force, strong medical affairs presence, hub/patient support and payer engagement) and management emphasizes building allergist trust and reducing physician-office friction. International strategy: no additional clinical studies required to file in U.K., EU, Canada — potential reach of ~1 billion people across U.S./E.U./U.K./Canada if approved. Pipeline: AQST-108 Phase I completed with no drug-related adverse events or appreciable systemic epinephrine absorption; directional biomarker signal (TSLP and CCL3/CCL4) observed in alopecia subjects suggesting potential dermatology indications. Business development: active BD discussions across regions; licensing opportunities being prioritized. Financing and liquidity: closed a $150M debt facility with Oaktree and extended RTW agreement, providing improved interest terms, deferred principal payments and access to additional tranches (including $20M upon FDA approval); company ended Q1 with ~$110M cash and projects >$150M cash at launch when combining existing cash, RTW and Oaktree availability (before additional deals). Financials: Q1 revenue $14.4M (+66% YoY) driven by licenses/royalties and manufacturing; Q1 net loss $8.1M vs $22.9M prior year; non-GAAP adjusted EBITDA loss improved to $(1.7)M from $(17.6)M; company maintained 2026 revenue expectation of $46–50M and non-GAAP adjusted EBITDA loss guidance of $(35)–(30)M (as of May 13, 2026) but is not updating full-year guidance pending near-term regulatory execution. Timeline/next milestones investors should watch: human factors protocol feedback from FDA (near-term), August top-line data update, potential Q3 NDA resubmission for Anaphylm, and further updates on AQST-108 development and ex-U.S. partnering/licensing.